Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Company Overview

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling. In parallel, Telomir maintains a preclinical pipeline of compounds designed to act on distinct molecular targets with the goal of delivering differentiated safety and efficacy profiles. Collaborative partnerships with academic institutions and contract research organizations support translational research efforts and accelerate compound progression from discovery through early clinical evaluation.

Headquartered in the United States, Telomir Pharmaceuticals is guided by an executive team with extensive experience in biopharmaceutical research, clinical development and regulatory affairs. While the company’s initial focus is on advancing its lead programs through clinical milestones in North America, management has articulated plans to pursue strategic alliances that could enable broader international development and commercialization. As a Nasdaq-listed entity, Telomir continues to refine its pipeline and expand its scientific platform with the goal of delivering innovative therapies to patients around the world.

Key Stats

• Today's Range: $1.26 to $1.43
• 50-Day Range: $1.19 to $1.48
• 52-Week Range: $1.05 to $3.10
• Volume: 1.12 million shs
• Average Volume: 88,135 shs
• Market Capitalization: $97.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Telomir Pharmaceuticals Stock Analysis - MarketRank™

Telomir Pharmaceuticals scored higher than 7% of companies evaluated by MarketBeat, and ranked 830th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Telomir Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Telomir Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Telomir Pharmaceuticals is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telomir Pharmaceuticals is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Telomir Pharmaceuticals has a P/B Ratio of 8.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.34% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 10.53, which indicates bearish sentiment.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently decreased by 11.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telomir Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telomir Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Telomir Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Telomir Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/19/2026
• Next Earnings (Estimated): 9/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TELO
• Previous Symbol: NASDAQ:TELO
• CIK: 1971532
• Web: telomirpharma.com
• Phone: (737)-289-0835
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -201.23%
• Return on Assets: -172.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.00
• Quick Ratio: 7.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 8.35

Miscellaneous

• Outstanding Shares: 68,780,000
• Free Float: N/A
• Market Cap: $97.67 million
• Optionable: N/A
• Beta: -0.24